Income Statement (TTM)
Assembly Biosciences, Inc. Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Administrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.
All numbers are times 1,000,000 except per share units.
|
2020 09-30 |
2020 12-31 |
2021 03-31 |
2021 06-30 |
2021 09-30 |
2021 12-31 |
2022 03-31 |
2022 06-30 |
2022 09-30 |
2023 12-31 |
2024 03-31 |
2024 06-30 |
2024 09-30 |
2024 12-31 |
2025 03-31 |
2025 06-30 |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 83 | 79 | 75 | 36 | 7 | 6 | 6 | 6 | 0 | 7 | 13 | 21 | 28 | 29 | 32 | 33 |
| Change (%) | -4.50 | -5.16 | -52.48 | -79.55 | -14.22 | 0.00 | 0.00 | -100.00 | ∞ | 80.76 | 65.90 | 31.87 | 0.68 | 12.74 | 3.40 | |
| % of Revenue | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | |
| Cost Of Sales | 95 | 101 | 97 | 94 | 86 | 70 | 69 | 65 | 64 | 49 | 46 | 50 | 53 | 56 | 59 | 59 |
| Change (%) | 6.12 | -4.43 | -2.56 | -8.97 | -18.34 | -1.92 | -5.17 | -1.75 | -23.71 | -5.46 | 8.08 | 5.39 | 6.22 | 5.31 | -0.23 | |
| % of Revenue | 115.29 | 128.10 | 129.09 | 264.72 | 1,178.16 | 1,121.67 | 1,100.10 | 1,043.22 | 682.67 | 357.06 | 232.61 | 185.90 | 196.12 | 183.20 | 176.77 | |
| Gross Operating Profit | -13 | -22 | -22 | -59 | -79 | -64 | -63 | -59 | -64 | -42 | -33 | -28 | -24 | -27 | -27 | -26 |
| Change (%) | 75.57 | -1.85 | 169.09 | 33.87 | -18.72 | -2.11 | -5.69 | 8.66 | -34.89 | -20.25 | -14.41 | -14.58 | 12.66 | -2.41 | -4.59 | |
| % of Revenue | -15.29 | -28.10 | -29.09 | -164.72 | -1,078.16 | -1,021.67 | -1,000.10 | -943.22 | -582.67 | -257.06 | -132.61 | -85.90 | -96.12 | -83.20 | -76.77 | |
| SG&A | 39 | 37 | 37 | 34 | 29 | 29 | 26 | 25 | 24 | 23 | 23 | 22 | 22 | 18 | 18 | 18 |
| Change (%) | -5.63 | -0.07 | -6.93 | -14.68 | -2.55 | -9.64 | -2.47 | -5.51 | -3.48 | -1.65 | -2.17 | 0.28 | -18.54 | -0.70 | 0.65 | |
| % of Revenue | 47.16 | 46.60 | 49.10 | 96.17 | 401.15 | 455.76 | 411.83 | 401.66 | 319.82 | 174.02 | 102.62 | 78.04 | 63.14 | 55.61 | 54.13 | |
| R&D | ||||||||||||||||
| Change (%) | ||||||||||||||||
| % of Revenue | ||||||||||||||||
| OpEx | 135 | 138 | 134 | 129 | 115 | 99 | 95 | 90 | 88 | 72 | 69 | 72 | 75 | 74 | 77 | 77 |
| Change (%) | 2.70 | -3.27 | -3.76 | -10.49 | -14.33 | -4.15 | -4.43 | -2.80 | -18.25 | -4.24 | 4.72 | 3.82 | -1.10 | 3.85 | -0.02 | |
| % of Revenue | 162.44 | 174.70 | 178.18 | 360.89 | 1,579.32 | 1,577.42 | 1,511.93 | 1,444.88 | 1,002.50 | 531.08 | 335.24 | 263.94 | 259.26 | 238.81 | 230.91 | |
| Operating Income | -52 | -59 | -59 | -93 | -108 | -92 | -88 | -84 | -88 | -65 | -56 | -51 | -46 | -45 | -45 | -44 |
| Change (%) | 14.24 | -0.74 | 58.55 | 15.97 | -14.33 | -4.43 | -4.75 | 4.43 | -26.40 | -13.66 | -9.47 | -8.10 | -2.19 | -1.73 | -2.49 | |
| % of Revenue | -62.44 | -74.70 | -78.18 | -260.89 | -1,479.32 | -1,477.42 | -1,411.93 | -1,344.88 | -902.50 | -431.08 | -235.24 | -163.94 | -159.26 | -138.81 | -130.91 | |
| Interest Expense | ||||||||||||||||
| Change (%) | ||||||||||||||||
| % of Revenue | ||||||||||||||||
| Net Income | -50 | -62 | -63 | -94 | -109 | -130 | -126 | -127 | -131 | -61 | -51 | -46 | -41 | -40 | -40 | -39 |
| Change (%) | 24.76 | 0.88 | 49.23 | 16.52 | 19.12 | -3.16 | 0.69 | 3.43 | -53.24 | -16.12 | -11.18 | -10.54 | -1.54 | -0.64 | -2.39 | |
| % of Revenue | -60.14 | -78.57 | -83.57 | -262.46 | -1,495.21 | -2,076.35 | -2,010.65 | -2,024.50 | -854.78 | -396.62 | -212.33 | -144.05 | -140.87 | -124.15 | -117.20 | |
Source: Capital IQ
